Navigation Links
Curing addiction with cannabis medicines
Date:3/7/2008

Smokers trying to quit in the future could do it with the help of cannabis based medicines, according to research from The University of Nottingham.

Teams of pharmacologists, studying the cannabis-like compounds which exist naturally in our bodies (endocannabinoids), are exploring the potential for medical treatment. This includes treating conditions as diverse as obesity, diabetes, depression and addiction to substances like nicotine.

Scientists have known about endocannabinoids since the mid-1990s. This led to an explosion in the number of researchers looking into the future medical uses of cannabinoids and cannabis compounds.

Dr Steve Alexander, Associate Professor in the School of Biomedical Sciences, focused on a number of these projects in editing the first themed podcast for the British Journal of Pharmacology.

Dr Alexander said: It is clear that there is very realistic potential for cannabinoids as medicines. Scientists are looking at a range of possible applications.

One of these researchers is Professor David Kendall, a cellular pharmacologist at the University: The brain is full of cannabinoid receptors. And so, not surprisingly with diseases like depression and anxiety, theres a great deal of interest in exploiting these receptors and in doing so, developing anti-depressant compounds.

Addiction is a real target researchers like Professor Kendall believe the endocannabinoids could be a crucial link to addictive behaviour: We know that the endocannabinoid system is intimately involved in reward pathways and drug seeking behaviour. So this tends to indicate that that if the link involving endocannabinoids and the reward pathway, using inhibitors, can be interrupted, it could turn down the drive to seek addictive agents like nicotine.

Because cannabinoids have also been shown to bring down blood pressure, it is hoped that related compounds can be used in patients with conditions like hypertension.

Dr Michael Randall, a cardiovascular pharmacologist at the University has looked at how endocannabinoids cause blood vessels to relax. This could have many implications, Dr Randall said. The endocannabinoids appear to lower blood pressure under certain conditions; states of shock for example. If the endocannabinoids are of physiological importance, this could have real therapeutic possibilities.

In terms of getting better medicines the endocannabinoid system has a lot to offer, said Dr Alexander. The range of cannabis-related medicines is currently limited, but by increasing our knowledge in this area we can increase our stock.


'/>"/>

Contact: Dr. Steven Alexander
steve.alexander@nottingham.ac.uk
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nations Economy by Investing in Early Childhood
2. Pharmaceutical Product Commercialization & Governance Best Practices: Securing Talent for Highly-Effective Brand Teams
3. Greenway Experiences Quick Success in the Community EHR Marketplace by Securing Contracts with 10 Community-Based Health Organizations
4. Lessons Learned in Securing Top Talent During University Recruiting
5. Novadaq Resumes Normal Business Operations by Securing ICG for SPY
6. NEWSWEEK Cover: The Hunt for an Addiction Vaccine
7. Aussie neuroscientist tests addiction drug
8. UTMB wins $3.4 million federal grant to study addiction-recovery drugs
9. ARMSRx Tackles the New Rx Addiction -- Pharmacy Benefit Audits
10. DNA (driver of nicotine addiction)
11. Cleveland Addiction Agency and National Association Partner to Help Clergy Counsel the Children of Alcoholics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology: